DurelliLCocitoDRiccioA. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: Clinical-immunologic correlations. Neurology1986; 36(2): 238–243.
2.
MilliganNMNewcombeRCompstonDA.A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry1987; 50(5): 511–516.
3.
KapoorNKeeverCALeongN. Effects of ex vivo treatment with methylprednisolone and vincristine on bone marrow lymphohematopoietic cells. Prog Clin Biol Res1992; 377: 49–56.
4.
LublinF and Hu23F2G MS Study Group. A phase II trial of anti-CD11/CD18 monoclonal antibody in acute exacerbations of Multiple Sclerosis (Abstract S45.006). Neurology1999; 52(suppl. 2): A290–A291.
5.
BeckRWClearyPABacklundJC.The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology1994; 101(11): 1771–1778.
6.
BeckRWTrobeJD.What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology1995; 102(10): 1504–1508.
7.
BeckRW.Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis. Lancet1997; 349(9066): 1696.
8.
BeckRWTrobeJDMokePS. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: Experience of the optic neuritis treatment trial. Arch Ophthalmol2003; 121(7): 944–949.
9.
BarnesDHughesRAMorrisRW. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet1997; 349(9056): 902–906.
10.
AlamSMKyriakidesTLawdenM. Methylprednisolone in multiple sclerosis: A comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry1993; 56(11): 1219–1220.
11.
Ramo-TelloCGrau-LopezLTintoreM. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler2014; 20: 717–725.
12.
MartinelliVPulizziAAnnovazziP. A single blind, randomized MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses. Neurology2009; 73: 1842–1848.
13.
MorrowSAStoianCADmitrovicJ. The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology2004; 63: 1079–1080.
14.
BurtonJMO’ConnorPWHoholM. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev2012; 12: CD006921.
15.
Le PageEVeillardDLaplaudD. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): A randomised, controlled, double-blind, non-inferiority trial. Lancet386: 974–981.
16.
LublinFDBaierMCutterG.Effect of relapses on development of residual deficit in multiple sclerosis. Neurology2003; 61: 1528–1532.
17.
ChatawayJ.Oral versus intravenous steroids in multiple sclerosis relapses: A perennial question?Mult Scler2014; 20(6): 643–645.
18.
SormaniMSignoriAStromilloM. Refining response to treatment as defined by the Modified Rio Score. Mult Scler2013; 19(9): 1246–1247.
